• Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss 

      Zahoor, Muhammad; Westhrin, Marita; Aass, Kristin Roseth; Moen, Siv Helen; Misund, Kristine; Psonka-Antonczyk, Katarzyna Maria; Giliberto, Mariaserena; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2017)
      Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The ...
    • Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells 

      Starheim, Kristian Kobbenes; Holien, Toril; Misund, Kristine; Johansson, Ida; Baranowska, Katarzyna Anna; Sponaas, Anne Marit; Hella, Hanne; Buene, Glenn; Waage, Anders; Sundan, Anders; Bjørkøy, Geir (Journal article; Peer reviewed, 2016)
      Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, ...